nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0696	0.126	CbGbCtD
Solifenacin—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0654	0.119	CbGbCtD
Solifenacin—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0654	0.119	CbGbCtD
Solifenacin—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0592	0.107	CbGbCtD
Solifenacin—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0592	0.107	CbGbCtD
Solifenacin—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0511	0.0925	CbGbCtD
Solifenacin—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0496	0.0898	CbGbCtD
Solifenacin—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0448	0.0812	CbGbCtD
Solifenacin—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0448	0.0812	CbGbCtD
Solifenacin—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.043	0.0779	CbGbCtD
Solifenacin—CHRM5—skin of body—acquired immunodeficiency syndrome	0.000735	0.0966	CbGeAlD
Solifenacin—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.000627	0.0015	CcSEcCtD
Solifenacin—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000626	0.0015	CcSEcCtD
Solifenacin—Erythema multiforme—Lamivudine—acquired immunodeficiency syndrome	0.000626	0.0015	CcSEcCtD
Solifenacin—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000625	0.0015	CcSEcCtD
Solifenacin—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.000625	0.0015	CcSEcCtD
Solifenacin—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.000624	0.0015	CcSEcCtD
Solifenacin—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000622	0.00149	CcSEcCtD
Solifenacin—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000621	0.00149	CcSEcCtD
Solifenacin—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.00062	0.00149	CcSEcCtD
Solifenacin—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.00062	0.00149	CcSEcCtD
Solifenacin—Cough—Efavirenz—acquired immunodeficiency syndrome	0.000619	0.00148	CcSEcCtD
Solifenacin—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000618	0.00148	CcSEcCtD
Solifenacin—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.000615	0.00148	CcSEcCtD
Solifenacin—Dysgeusia—Ritonavir—acquired immunodeficiency syndrome	0.000615	0.00147	CcSEcCtD
Solifenacin—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.000613	0.00147	CcSEcCtD
Solifenacin—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.000612	0.00147	CcSEcCtD
Solifenacin—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.000611	0.00146	CcSEcCtD
Solifenacin—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000609	0.00146	CcSEcCtD
Solifenacin—Mental disorder—Saquinavir—acquired immunodeficiency syndrome	0.000608	0.00146	CcSEcCtD
Solifenacin—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000604	0.00145	CcSEcCtD
Solifenacin—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000604	0.00145	CcSEcCtD
Solifenacin—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000604	0.00145	CcSEcCtD
Solifenacin—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000603	0.00145	CcSEcCtD
Solifenacin—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.000602	0.00144	CcSEcCtD
Solifenacin—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000601	0.00144	CcSEcCtD
Solifenacin—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000601	0.00144	CcSEcCtD
Solifenacin—Headache—Amprenavir—acquired immunodeficiency syndrome	0.0006	0.00144	CcSEcCtD
Solifenacin—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.0006	0.00144	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.0006	0.00144	CcSEcCtD
Solifenacin—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000599	0.00144	CcSEcCtD
Solifenacin—Immune system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000598	0.00143	CcSEcCtD
Solifenacin—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000597	0.00143	CcSEcCtD
Solifenacin—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000595	0.00143	CcSEcCtD
Solifenacin—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000593	0.00142	CcSEcCtD
Solifenacin—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000592	0.00142	CcSEcCtD
Solifenacin—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	0.000592	0.00142	CcSEcCtD
Solifenacin—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.000591	0.00142	CcSEcCtD
Solifenacin—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000591	0.00142	CcSEcCtD
Solifenacin—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.00059	0.00142	CcSEcCtD
Solifenacin—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000586	0.00141	CcSEcCtD
Solifenacin—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000586	0.0014	CcSEcCtD
Solifenacin—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.000584	0.0014	CcSEcCtD
Solifenacin—CHRM4—nervous system—acquired immunodeficiency syndrome	0.000582	0.0764	CbGeAlD
Solifenacin—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.00058	0.00139	CcSEcCtD
Solifenacin—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000578	0.00139	CcSEcCtD
Solifenacin—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000576	0.00138	CcSEcCtD
Solifenacin—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000573	0.00137	CcSEcCtD
Solifenacin—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000569	0.00136	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000569	0.00136	CcSEcCtD
Solifenacin—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000568	0.00136	CcSEcCtD
Solifenacin—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000568	0.00136	CcSEcCtD
Solifenacin—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000565	0.00136	CcSEcCtD
Solifenacin—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000565	0.00135	CcSEcCtD
Solifenacin—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.000564	0.00135	CcSEcCtD
Solifenacin—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000563	0.00135	CcSEcCtD
Solifenacin—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000563	0.00135	CcSEcCtD
Solifenacin—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000562	0.00135	CcSEcCtD
Solifenacin—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.00056	0.00134	CcSEcCtD
Solifenacin—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.00056	0.0736	CbGeAlD
Solifenacin—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000559	0.00134	CcSEcCtD
Solifenacin—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000558	0.00134	CcSEcCtD
Solifenacin—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000555	0.00133	CcSEcCtD
Solifenacin—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000555	0.00133	CcSEcCtD
Solifenacin—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.000555	0.00133	CcSEcCtD
Solifenacin—Rash—Didanosine—acquired immunodeficiency syndrome	0.000551	0.00132	CcSEcCtD
Solifenacin—Infection—Delavirdine—acquired immunodeficiency syndrome	0.00055	0.00132	CcSEcCtD
Solifenacin—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.00055	0.00132	CcSEcCtD
Solifenacin—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00055	0.00132	CcSEcCtD
Solifenacin—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000548	0.00131	CcSEcCtD
Solifenacin—Headache—Didanosine—acquired immunodeficiency syndrome	0.000547	0.00131	CcSEcCtD
Solifenacin—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000546	0.00131	CcSEcCtD
Solifenacin—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000545	0.00131	CcSEcCtD
Solifenacin—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000544	0.0013	CcSEcCtD
Solifenacin—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000543	0.0013	CcSEcCtD
Solifenacin—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000542	0.0013	CcSEcCtD
Solifenacin—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000541	0.0013	CcSEcCtD
Solifenacin—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000539	0.00129	CcSEcCtD
Solifenacin—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000539	0.00129	CcSEcCtD
Solifenacin—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000538	0.00129	CcSEcCtD
Solifenacin—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000538	0.00129	CcSEcCtD
Solifenacin—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000536	0.00129	CcSEcCtD
Solifenacin—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000536	0.00128	CcSEcCtD
Solifenacin—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000533	0.00128	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000531	0.00127	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000529	0.00127	CcSEcCtD
Solifenacin—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000528	0.00127	CcSEcCtD
Solifenacin—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000528	0.00127	CcSEcCtD
Solifenacin—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000527	0.00126	CcSEcCtD
Solifenacin—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000527	0.00126	CcSEcCtD
Solifenacin—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000524	0.00126	CcSEcCtD
Solifenacin—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000523	0.00126	CcSEcCtD
Solifenacin—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000523	0.00125	CcSEcCtD
Solifenacin—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000522	0.00125	CcSEcCtD
Solifenacin—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000521	0.00125	CcSEcCtD
Solifenacin—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000519	0.00124	CcSEcCtD
Solifenacin—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000516	0.00124	CcSEcCtD
Solifenacin—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000515	0.00123	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000511	0.00122	CcSEcCtD
Solifenacin—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.00051	0.00122	CcSEcCtD
Solifenacin—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000505	0.00121	CcSEcCtD
Solifenacin—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000503	0.00121	CcSEcCtD
Solifenacin—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000503	0.00121	CcSEcCtD
Solifenacin—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000503	0.00121	CcSEcCtD
Solifenacin—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000503	0.00121	CcSEcCtD
Solifenacin—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000502	0.0012	CcSEcCtD
Solifenacin—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000501	0.0012	CcSEcCtD
Solifenacin—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000501	0.0012	CcSEcCtD
Solifenacin—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.0005	0.0012	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.0005	0.0012	CcSEcCtD
Solifenacin—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000499	0.0012	CcSEcCtD
Solifenacin—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000499	0.0012	CcSEcCtD
Solifenacin—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000498	0.00119	CcSEcCtD
Solifenacin—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000497	0.00119	CcSEcCtD
Solifenacin—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000495	0.00119	CcSEcCtD
Solifenacin—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000495	0.00119	CcSEcCtD
Solifenacin—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000495	0.00119	CcSEcCtD
Solifenacin—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000494	0.00118	CcSEcCtD
Solifenacin—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000492	0.00118	CcSEcCtD
Solifenacin—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000492	0.00118	CcSEcCtD
Solifenacin—Infection—Saquinavir—acquired immunodeficiency syndrome	0.00049	0.00117	CcSEcCtD
Solifenacin—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000488	0.00117	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000487	0.00117	CcSEcCtD
Solifenacin—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000487	0.00117	CcSEcCtD
Solifenacin—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000484	0.00116	CcSEcCtD
Solifenacin—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000483	0.00116	CcSEcCtD
Solifenacin—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000483	0.00116	CcSEcCtD
Solifenacin—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000482	0.00116	CcSEcCtD
Solifenacin—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000482	0.00115	CcSEcCtD
Solifenacin—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00048	0.00115	CcSEcCtD
Solifenacin—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000479	0.00115	CcSEcCtD
Solifenacin—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000479	0.00115	CcSEcCtD
Solifenacin—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000479	0.00115	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000478	0.00115	CcSEcCtD
Solifenacin—Rash—Stavudine—acquired immunodeficiency syndrome	0.000478	0.00115	CcSEcCtD
Solifenacin—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000478	0.00115	CcSEcCtD
Solifenacin—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000478	0.00115	CcSEcCtD
Solifenacin—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000477	0.00114	CcSEcCtD
Solifenacin—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000476	0.00114	CcSEcCtD
Solifenacin—Headache—Stavudine—acquired immunodeficiency syndrome	0.000475	0.00114	CcSEcCtD
Solifenacin—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000475	0.00114	CcSEcCtD
Solifenacin—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000474	0.00114	CcSEcCtD
Solifenacin—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000474	0.00114	CcSEcCtD
Solifenacin—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000473	0.00114	CcSEcCtD
Solifenacin—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000473	0.00113	CcSEcCtD
Solifenacin—Rash—Abacavir—acquired immunodeficiency syndrome	0.000471	0.00113	CcSEcCtD
Solifenacin—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.00047	0.00113	CcSEcCtD
Solifenacin—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.00047	0.00113	CcSEcCtD
Solifenacin—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00047	0.0617	CbGeAlD
Solifenacin—Headache—Abacavir—acquired immunodeficiency syndrome	0.000468	0.00112	CcSEcCtD
Solifenacin—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000467	0.00112	CcSEcCtD
Solifenacin—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000466	0.00112	CcSEcCtD
Solifenacin—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000466	0.00112	CcSEcCtD
Solifenacin—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000461	0.00111	CcSEcCtD
Solifenacin—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.00046	0.0011	CcSEcCtD
Solifenacin—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000458	0.0011	CcSEcCtD
Solifenacin—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000457	0.0011	CcSEcCtD
Solifenacin—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000456	0.00109	CcSEcCtD
Solifenacin—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000455	0.00109	CcSEcCtD
Solifenacin—CHRM5—nervous system—acquired immunodeficiency syndrome	0.000455	0.0597	CbGeAlD
Solifenacin—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000453	0.00109	CcSEcCtD
Solifenacin—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000452	0.00108	CcSEcCtD
Solifenacin—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000451	0.00108	CcSEcCtD
Solifenacin—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000451	0.00108	CcSEcCtD
Solifenacin—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00045	0.00108	CcSEcCtD
Solifenacin—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000445	0.00107	CcSEcCtD
Solifenacin—CHRM4—brain—acquired immunodeficiency syndrome	0.000444	0.0584	CbGeAlD
Solifenacin—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000444	0.00106	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000442	0.00106	CcSEcCtD
Solifenacin—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000442	0.00106	CcSEcCtD
Solifenacin—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.00044	0.00106	CcSEcCtD
Solifenacin—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00044	0.00105	CcSEcCtD
Solifenacin—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000438	0.00105	CcSEcCtD
Solifenacin—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000438	0.00105	CcSEcCtD
Solifenacin—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000438	0.00105	CcSEcCtD
Solifenacin—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.000438	0.0575	CbGeAlD
Solifenacin—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000436	0.00104	CcSEcCtD
Solifenacin—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000434	0.00104	CcSEcCtD
Solifenacin—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000434	0.00104	CcSEcCtD
Solifenacin—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000429	0.00103	CcSEcCtD
Solifenacin—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000427	0.00102	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000426	0.00102	CcSEcCtD
Solifenacin—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000425	0.00102	CcSEcCtD
Solifenacin—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000422	0.00101	CcSEcCtD
Solifenacin—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000422	0.00101	CcSEcCtD
Solifenacin—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000419	0.001	CcSEcCtD
Solifenacin—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000419	0.001	CcSEcCtD
Solifenacin—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000418	0.001	CcSEcCtD
Solifenacin—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000415	0.000996	CcSEcCtD
Solifenacin—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000415	0.000996	CcSEcCtD
Solifenacin—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000415	0.000995	CcSEcCtD
Solifenacin—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000414	0.000993	CcSEcCtD
Solifenacin—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000413	0.00099	CcSEcCtD
Solifenacin—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00041	0.000982	CcSEcCtD
Solifenacin—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000409	0.00098	CcSEcCtD
Solifenacin—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000408	0.000979	CcSEcCtD
Solifenacin—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000407	0.000976	CcSEcCtD
Solifenacin—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000406	0.000974	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000406	0.000974	CcSEcCtD
Solifenacin—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000405	0.000972	CcSEcCtD
Solifenacin—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000405	0.000972	CcSEcCtD
Solifenacin—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000405	0.000971	CcSEcCtD
Solifenacin—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000403	0.000967	CcSEcCtD
Solifenacin—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000402	0.000965	CcSEcCtD
Solifenacin—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000397	0.000953	CcSEcCtD
Solifenacin—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000392	0.00094	CcSEcCtD
Solifenacin—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000392	0.000939	CcSEcCtD
Solifenacin—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000391	0.000939	CcSEcCtD
Solifenacin—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.00039	0.000935	CcSEcCtD
Solifenacin—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.00039	0.000934	CcSEcCtD
Solifenacin—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000388	0.000929	CcSEcCtD
Solifenacin—Rash—Indinavir—acquired immunodeficiency syndrome	0.000386	0.000926	CcSEcCtD
Solifenacin—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000386	0.000926	CcSEcCtD
Solifenacin—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000385	0.000922	CcSEcCtD
Solifenacin—Headache—Indinavir—acquired immunodeficiency syndrome	0.000384	0.000921	CcSEcCtD
Solifenacin—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000383	0.000918	CcSEcCtD
Solifenacin—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000377	0.000905	CcSEcCtD
Solifenacin—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000374	0.000896	CcSEcCtD
Solifenacin—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000372	0.000892	CcSEcCtD
Solifenacin—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000368	0.000883	CcSEcCtD
Solifenacin—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000368	0.000881	CcSEcCtD
Solifenacin—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000366	0.000878	CcSEcCtD
Solifenacin—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000365	0.000875	CcSEcCtD
Solifenacin—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000365	0.000875	CcSEcCtD
Solifenacin—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000364	0.000873	CcSEcCtD
Solifenacin—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000363	0.000871	CcSEcCtD
Solifenacin—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000363	0.00087	CcSEcCtD
Solifenacin—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000362	0.000869	CcSEcCtD
Solifenacin—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000354	0.000848	CcSEcCtD
Solifenacin—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000352	0.000845	CcSEcCtD
Solifenacin—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000349	0.000838	CcSEcCtD
Solifenacin—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000349	0.000837	CcSEcCtD
Solifenacin—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000349	0.000836	CcSEcCtD
Solifenacin—CHRM5—brain—acquired immunodeficiency syndrome	0.000347	0.0457	CbGeAlD
Solifenacin—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000347	0.000832	CcSEcCtD
Solifenacin—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000347	0.000831	CcSEcCtD
Solifenacin—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000344	0.000825	CcSEcCtD
Solifenacin—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000339	0.000812	CcSEcCtD
Solifenacin—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000337	0.000809	CcSEcCtD
Solifenacin—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000333	0.000798	CcSEcCtD
Solifenacin—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000329	0.000789	CcSEcCtD
Solifenacin—CHRM3—digestive system—acquired immunodeficiency syndrome	0.000329	0.0432	CbGeAlD
Solifenacin—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000326	0.000782	CcSEcCtD
Solifenacin—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000326	0.000781	CcSEcCtD
Solifenacin—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000323	0.000775	CcSEcCtD
Solifenacin—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000323	0.000774	CcSEcCtD
Solifenacin—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000321	0.00077	CcSEcCtD
Solifenacin—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000313	0.000752	CcSEcCtD
Solifenacin—CHRM2—nervous system—acquired immunodeficiency syndrome	0.000312	0.041	CbGeAlD
Solifenacin—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000311	0.000746	CcSEcCtD
Solifenacin—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000311	0.000745	CcSEcCtD
Solifenacin—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000311	0.000745	CcSEcCtD
Solifenacin—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000309	0.000741	CcSEcCtD
Solifenacin—CHRM1—lung—acquired immunodeficiency syndrome	0.000307	0.0403	CbGeAlD
Solifenacin—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000304	0.00073	CcSEcCtD
Solifenacin—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.0003	0.0395	CbGeAlD
Solifenacin—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000299	0.000717	CcSEcCtD
Solifenacin—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000297	0.000711	CcSEcCtD
Solifenacin—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000296	0.000711	CcSEcCtD
Solifenacin—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000295	0.000707	CcSEcCtD
Solifenacin—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000293	0.000702	CcSEcCtD
Solifenacin—CHRM1—nervous system—acquired immunodeficiency syndrome	0.000284	0.0373	CbGeAlD
Solifenacin—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000279	0.00067	CcSEcCtD
Solifenacin—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.000273	0.0359	CbGeAlD
Solifenacin—CHRM3—nervous system—acquired immunodeficiency syndrome	0.000254	0.0334	CbGeAlD
Solifenacin—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.000245	0.0322	CbGeAlD
Solifenacin—CHRM2—brain—acquired immunodeficiency syndrome	0.000238	0.0313	CbGeAlD
Solifenacin—CHRM1—brain—acquired immunodeficiency syndrome	0.000217	0.0285	CbGeAlD
Solifenacin—CHRM3—brain—acquired immunodeficiency syndrome	0.000194	0.0255	CbGeAlD
Solifenacin—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000181	0.0237	CbGeAlD
Solifenacin—CYP3A4—blood—acquired immunodeficiency syndrome	0.000172	0.0226	CbGeAlD
Solifenacin—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.00014	0.0184	CbGeAlD
Solifenacin—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000134	0.0177	CbGeAlD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000128	0.00544	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000125	0.00532	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000124	0.0053	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000123	0.00525	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000122	0.00521	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000122	0.00521	CbGpPWpGaD
Solifenacin—CHRM4—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000122	0.0052	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000114	0.00487	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000114	0.00484	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000113	0.00481	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000112	0.00479	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000112	0.00479	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000111	0.00475	CbGpPWpGaD
Solifenacin—CHRM4—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00011	0.00469	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000109	0.00466	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000107	0.00455	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000107	0.00455	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000107	0.00455	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000106	0.00454	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000106	0.0045	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000105	0.00449	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000105	0.00449	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000104	0.00445	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000103	0.00441	CbGpPWpGaD
Solifenacin—CHRM4—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000102	0.00435	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000101	0.00431	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000101	0.0043	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.0001	0.00428	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.0001	0.00427	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	9.99e-05	0.00426	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	9.91e-05	0.00423	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	9.89e-05	0.00422	CbGpPWpGaD
Solifenacin—CHRM5—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	9.77e-05	0.00417	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.71e-05	0.00414	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.71e-05	0.00414	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.7e-05	0.00414	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	9.49e-05	0.00405	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.3e-05	0.00397	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.3e-05	0.00397	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.29e-05	0.00396	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	9.25e-05	0.00395	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	9.15e-05	0.0039	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	9.12e-05	0.00389	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	9.09e-05	0.00387	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	9.03e-05	0.00385	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	8.86e-05	0.00378	CbGpPWpGaD
Solifenacin—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.74e-05	0.00373	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	8.6e-05	0.00367	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	8.6e-05	0.00367	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.58e-05	0.00366	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	8.57e-05	0.00366	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	8.57e-05	0.00366	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	8.49e-05	0.00362	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	8.49e-05	0.00362	CbGpPWpGaD
Solifenacin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.37e-05	0.00357	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.22e-05	0.0035	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	8.12e-05	0.00346	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.7e-05	0.00328	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.68e-05	0.00327	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.6e-05	0.00324	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.39e-05	0.00315	CbGpPWpGaD
Solifenacin—CHRM2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	7.32e-05	0.00312	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.08e-05	0.00302	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.97e-05	0.00297	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.94e-05	0.00296	CbGpPWpGaD
Solifenacin—CHRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.88e-05	0.00293	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.88e-05	0.00293	CbGpPWpGaD
Solifenacin—CHRM3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.86e-05	0.00292	CbGpPWpGaD
Solifenacin—CHRM2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	6.79e-05	0.0029	CbGpPWpGaD
Solifenacin—CHRM4—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.66e-05	0.00284	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—TAT—acquired immunodeficiency syndrome	6.63e-05	0.00283	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.55e-05	0.00279	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.55e-05	0.00279	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.54e-05	0.00279	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.53e-05	0.00278	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.53e-05	0.00278	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.52e-05	0.00278	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.47e-05	0.00276	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.47e-05	0.00276	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.46e-05	0.00275	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.4e-05	0.00273	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.38e-05	0.00272	CbGpPWpGaD
Solifenacin—CHRM5—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.38e-05	0.00272	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.32e-05	0.00269	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.24e-05	0.00266	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.22e-05	0.00265	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.16e-05	0.00263	CbGpPWpGaD
Solifenacin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.89e-05	0.00251	CbGpPWpGaD
Solifenacin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.88e-05	0.00251	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.86e-05	0.0025	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.84e-05	0.00249	CbGpPWpGaD
Solifenacin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.82e-05	0.00248	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.79e-05	0.00247	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.77e-05	0.00246	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.71e-05	0.00244	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AGPS—acquired immunodeficiency syndrome	5.64e-05	0.0024	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.61e-05	0.00239	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.61e-05	0.00239	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.61e-05	0.00239	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.59e-05	0.00238	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.49e-05	0.00234	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.49e-05	0.00234	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.37e-05	0.00229	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.37e-05	0.00229	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.3e-05	0.00226	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.26e-05	0.00224	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.26e-05	0.00224	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.08e-05	0.00216	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.07e-05	0.00216	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.98e-05	0.00213	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.98e-05	0.00213	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.98e-05	0.00212	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.97e-05	0.00212	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.92e-05	0.0021	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.85e-05	0.00207	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.77e-05	0.00204	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.77e-05	0.00204	CbGpPWpGaD
Solifenacin—CHRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.49e-05	0.00191	CbGpPWpGaD
Solifenacin—CHRM3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.47e-05	0.00191	CbGpPWpGaD
Solifenacin—CHRM2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.43e-05	0.00189	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	4.27e-05	0.00182	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.18e-05	0.00178	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.11e-05	0.00175	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4e-05	0.00171	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.95e-05	0.00169	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.94e-05	0.00168	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.94e-05	0.00168	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.94e-05	0.00168	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.92e-05	0.00167	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.9e-05	0.00166	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.89e-05	0.00166	CbGpPWpGaD
Solifenacin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.84e-05	0.00164	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.79e-05	0.00162	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.78e-05	0.00161	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.78e-05	0.00161	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.77e-05	0.00161	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.77e-05	0.00161	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.76e-05	0.0016	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.74e-05	0.00159	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.73e-05	0.00159	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.73e-05	0.00159	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.7e-05	0.00158	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.7e-05	0.00158	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.69e-05	0.00157	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.69e-05	0.00157	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.65e-05	0.00156	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.65e-05	0.00156	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.63e-05	0.00155	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.6e-05	0.00154	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.58e-05	0.00153	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.57e-05	0.00152	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.56e-05	0.00152	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.53e-05	0.0015	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.46e-05	0.00148	CbGpPWpGaD
Solifenacin—CHRM2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	3.45e-05	0.00147	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.42e-05	0.00146	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.42e-05	0.00146	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.41e-05	0.00145	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.37e-05	0.00144	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.36e-05	0.00143	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.36e-05	0.00143	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.35e-05	0.00143	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.35e-05	0.00143	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.32e-05	0.00141	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.32e-05	0.00141	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.32e-05	0.00141	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.27e-05	0.0014	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.13e-05	0.00134	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3e-05	0.00128	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.94e-05	0.00126	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.94e-05	0.00126	CbGpPWpGaD
Solifenacin—CHRM1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	2.85e-05	0.00122	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.82e-05	0.0012	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.82e-05	0.0012	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.82e-05	0.0012	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.81e-05	0.0012	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.78e-05	0.00119	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.77e-05	0.00118	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.76e-05	0.00118	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.74e-05	0.00117	CbGpPWpGaD
Solifenacin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.7e-05	0.00115	CbGpPWpGaD
Solifenacin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.69e-05	0.00115	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	2.59e-05	0.0011	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.56e-05	0.00109	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.55e-05	0.00109	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.54e-05	0.00108	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.53e-05	0.00108	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.52e-05	0.00108	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.52e-05	0.00107	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.51e-05	0.00107	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.5e-05	0.00107	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.49e-05	0.00106	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.34e-05	0.000996	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.33e-05	0.000993	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.31e-05	0.000983	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.3e-05	0.000982	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.3e-05	0.000979	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.27e-05	0.00097	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.24e-05	0.000955	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.21e-05	0.000941	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	2.2e-05	0.00094	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.17e-05	0.000927	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.15e-05	0.000915	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.11e-05	0.000901	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.11e-05	0.0009	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.11e-05	0.000898	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.08e-05	0.000889	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.08e-05	0.000888	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.02e-05	0.000861	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.99e-05	0.000847	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.99e-05	0.000847	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.98e-05	0.000844	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.98e-05	0.000844	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.97e-05	0.000842	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.96e-05	0.000836	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.96e-05	0.000836	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.93e-05	0.000824	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.89e-05	0.000806	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.51e-05	0.000644	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.51e-05	0.000642	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.49e-05	0.000636	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.49e-05	0.000634	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.48e-05	0.000632	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.47e-05	0.000626	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.47e-05	0.000625	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.46e-05	0.000623	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.45e-05	0.000617	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.36e-05	0.00058	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.36e-05	0.000578	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.34e-05	0.000573	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.33e-05	0.000568	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.33e-05	0.000566	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.31e-05	0.00056	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.17e-05	0.000497	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.16e-05	0.000495	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	1.16e-05	0.000493	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.12e-05	0.000476	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.11e-05	0.000474	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.86e-06	0.000335	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.84e-06	0.000334	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.82e-06	0.000334	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.8e-06	0.000333	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.76e-06	0.000331	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.72e-06	0.000329	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.85e-06	0.000292	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.56e-06	0.00028	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.62e-06	0.000197	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.61e-06	0.000196	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.56e-06	0.000195	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	4.52e-06	0.000193	CbGpPWpGaD
